Sign in
AGEN Stock Price, Chart, Stats & News
Agenus Inc.
Save
Agenus Inc. (AGEN) does not currently pay a dividend.
413.51M
Market cap
3.94x
Current P/E
3.73x
Forward P/E
AGEN chart
Fundamentals
Gross margin | 35.68% |
Operating margin | -17.66% |
Pretax margin | -2.70% |
Net margin | 0.10% |
Effective tax rate | – |
ROA | 0.05% |
ROE | -0.04% |
D/E | -1.24x |
Interest coverage ratio | -0.36x |
AGEN valuation
P/E | 3.94x |
P/S | 1.14x |
P/B | -0.44x |
P/CF | -0.76x |
P/FCF | -0.82x |
P/OCF | -0.76x |
PEG | 12.39x |
EV multiple | -2.83x |
About
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant.
Similar securities
Based on sector and market capitalization
Report issue